Paper35112265
State-of-the-art review on management of end-stage heart failure in amyloidosis: transplant and beyond.
Kumar S and 3 others. Heart Fail Rev, 2022. Cited by 10 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. State-of-the-art review on management of end-stage heart failure in amyloidosis: transplant and beyond. Papers, record 35112265. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/35112265
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- State-of-the-art review on management of end-stage heart failure in amyloidosis: transplant and beyond.
- PubMed
Topics4
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Amyloidosis | Major topic |
| Heart Failure | Major topic |
| Heart Transplantation | Major topic |
| Humans |
Source PubMed
References51
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 29,954,863 | Amyloid seeding of transthyretin by ex vivo cardiac fibrils and its inhibition. | Proc Natl Acad Sci U S A | 2018 | https://conductscience.org/library/papers/29954863 | PubMed |
| 2 | 14,734,330 | High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. | Ann Intern Med | 2004 | https://conductscience.org/library/papers/14734330 | PubMed |
| 3 | 20,733,534 | Cardiac transplantation followed by dose-intensive melphalan and autologous stem-cell transplantation for light chain amyloidosis and heart failure. | Transplantation | 2010 | https://conductscience.org/library/papers/20733534 | PubMed |
| 4 | 1,540,601 | Heart transplantation for restrictive cardiomyopathy: development of cardiac amyloidosis in preexisting monoclonal gammopathy. | J Heart Lung Transplant | 1992 | https://conductscience.org/library/papers/1540601 | PubMed |
| 5 | 1,934,428 | Progression of systemic disease and reduced long-term survival in patients with cardiac amyloidosis undergoing heart transplantation. Follow-up results of a multicenter survey. | Circulation | 1991 | https://conductscience.org/library/papers/1934428 | PubMed |
| 6 | 29,677,073 | Outcomes After Cardiac Transplant for Wild Type Transthyretin Amyloidosis. | Transplantation | 2018 | https://conductscience.org/library/papers/29677073 | PubMed |
| 7 | 21,828,140 | Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients. | Blood | 2011 | https://conductscience.org/library/papers/21828140 | PubMed |
| 8 | 33,621,542 | Cardiac transplantation outcomes in patients with amyloid cardiomyopathy. | Am Heart J | 2021 | https://conductscience.org/library/papers/33621542 | PubMed |
| 9 | 30,759,167 | Infectious complications and NK cell depletion following daratumumab treatment of Multiple Myeloma. | PLoS One | 2019 | https://conductscience.org/library/papers/30759167 | PubMed |
| 10 | 9,052,371 | Effectiveness of cardiac transplantation for primary (AL) cardiac amyloidosis. | Am J Cardiol | 1997 | https://conductscience.org/library/papers/9052371 | PubMed |
| 11 | 31,978,210 | Safety, tolerability, and response rates of daratumumab in relapsed AL amyloidosis: results of a phase 2 study. | Blood | 2020 | https://conductscience.org/library/papers/31978210 | PubMed |
| 12 | 28,615,223 | Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis. | Blood | 2017 | https://conductscience.org/library/papers/28615223 | PubMed |
| 13 | 7,572,642 | Recurrence of primary (AL) amyloidosis in a transplanted heart with four-year survival. | Am J Cardiol | 1995 | https://conductscience.org/library/papers/7572642 | PubMed |
| 14 | 11,156,673 | Long term results of heart transplantation in patients with amyloid heart disease. | Heart | 2001 | https://conductscience.org/library/papers/11156673 | PubMed |
| 15 | 32,917,391 | Outcomes of Heart Transplantation in Cardiac Amyloidosis Patients: A Single Center Experience. | Transplant Proc | 2021 | https://conductscience.org/library/papers/32917391 | PubMed |
| 16 | 4,872,136 | A clinical analysis of the course and prognosis of forty-two patients with amyloidosis. | Am J Med | 1968 | https://conductscience.org/library/papers/4872136 | PubMed |
| 17 | 29,802,083 | Interagency registry for mechanically assisted circulatory support report on the total artificial heart. | J Heart Lung Transplant | 2018 | https://conductscience.org/library/papers/29802083 | PubMed |
| 18 | 32,241,538 | Percutaneous Left Axillary Artery Placement of Intra-Aortic Balloon Pump in Advanced Heart Failure Patients. | JACC Heart Fail | 2020 | https://conductscience.org/library/papers/32241538 | PubMed |
| 19 | 16,210,334 | Sequential heart and autologous stem cell transplantation for systemic AL amyloidosis. | Blood | 2006 | https://conductscience.org/library/papers/16210334 | PubMed |
| 20 | 32,623,785 | United network for organ sharing outcomes after heart transplantation for al compared to ATTR cardiac amyloidosis. | Clin Transplant | 2020 | https://conductscience.org/library/papers/32623785 | PubMed |
Cited by5
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 10 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41,524,065 | A Comprehensive Review of the Management of Light-Chain (AL) and Transthyretin (ATTR) Cardiac Amyloidosis. | Rev Cardiovasc Med | 2025 | https://conductscience.org/library/papers/41524065 | PubMed |
| 40,335,224 | Current Landscape of Therapies for Transthyretin Amyloid Cardiomyopathy. | JACC Heart Fail | 2025 | https://conductscience.org/library/papers/40335224 | PubMed |
| 39,551,565 | Evolving Strategies in Cardiac Amyloidosis: From Mechanistic Discoveries to Diagnostic and Therapeutic Advances. | Cardiol Clin | 2025 | https://conductscience.org/library/papers/39551565 | PubMed |
| 37,190,153 | Cardiotoxicity, Cardioprotection, and Prognosis in Survivors of Anticancer Treatment Undergoing Cardiac Surgery: Unmet Needs. | Cancers (Basel) | 2023 | https://conductscience.org/library/papers/37190153 | PubMed |
| 36,620,138 | Left ventricular myocardial work index and short-term prognosis in patients with light-chain cardiac amyloidosis: a retrospective cohort study. | Quant Imaging Med Surg | 2023 | https://conductscience.org/library/papers/36620138 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| TTR | 7,276 | PubTator's text mining | https://conductscience.org/library/genes/7276 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/35112265
GET https://conductscience.org/api/papers/v1/35112265/references?page=2